Anti-VEGF in Real-world

Last updated: February 2, 2022
Sponsor: Wenbin Wei
Overall Status: Active - Recruiting

Phase

N/A

Condition

Macular Edema

Diabetic Retinopathy

Diabetic Macular Edema

Treatment

N/A

Clinical Study ID

NCT05222633
Anti-VEGF in real-world
  • Ages 35-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-vascular endothelial growth factor therapy drugs. In the current study, the primary aim is to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabeticretinopathy (PDR), retinal vein occlusions related macular edema, and choroidalneovascular (CNV) secondary to multiple retinal diseases.
  • Undergo intravitreal anti-VEGF therapy

Exclusion

Exclusion Criteria:

  • unable to receive OCT examination
  • Severe corneal opacity, cataract that affect OCT examination

Study Design

Total Participants: 1000
Study Start date:
January 01, 2022
Estimated Completion Date:
May 01, 2023

Study Description

Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferative diabetic retinopathy / proliferative diabetic retinopathy, retinal vein occlusions related macular edema, and choroidal neovascularization secondary to multiple retinal diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and Conbercept are major types of anti-VEGF drugs. In the current study, the primary aim is to aim to observe the visual acuity, anatomy effect of anti-vascular endothelial growth factor therapy in the real-world setting.

Connect with a study center

  • Wen-Bin Wei

    Beijing, Beijing 100730
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.